MedTrace Logo

Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old

NCT02432911 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2016-10-07

No results posted yet for this study

Summary

This study focus on the comparison of CAG regimen to the low dose cytarabine therapy in elderly AML patients who are unfit or unwilling to receive intensive chemotherapy.

Conditions

Interventions

DRUG

CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)

Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.

DRUG

low dose cytarabine

cytarabine 20mg bid for 10 days.

Sponsors & Collaborators

  • Jianxiang Wang

    lead UNKNOWN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-05-31
Completion
2021-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02432911 on ClinicalTrials.gov